The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump. In this article, we are going to take ...

The U.K.-headquartered chip design ... Arm Holdings Plc. is reportedly planning to launch its first-ever complete semiconductor after securing Facebook’s parent company Meta Platforms Inc. as ...

Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.

Kosuke Okahara / Bloomberg / Getty Images Shares of Arm surged Thursday following a report the chip designer is developing its own chip, with tech giant Meta set to be one of its first customers.

To create one of the most advanced ... trogocytosis as a consideration in the design of future cell therapies, Chen said. Importantly, she added, the study changes scientists’ understanding ...

Investigations have shown that a single proven methodology yields ... VLSI design engineer he went on to form ARM's Design Methodology Group in 1995. Biggs currently works as a Consultant Engineer in ...

Clinical trial design is a key aspect of the successful ... Here this group conducts a single-arm, open-label, phase II trial assessing the combination therapy of regorafenib (tyrosine kinase ...

Arm does not design its own chips ... increased by 14% year over year to $403 million. It signed one additional Arm Total Access agreement in the quarter, bringing the total to 40.

Asked what the weather is like outside, one ... research implies that the robot may be even less humanoid than Amazon’s. Rumors surrounding the upcoming release have described the hub as “a ...